GRI Bio Seeks Shareholder Nod for Reverse Stock Split

TL;DR

**GRI Bio's reverse split is a desperate move to stay listed on Nasdaq; don't expect a fundamental turnaround from this alone.**

AI Summary

GRI Bio, Inc. (GRI) is seeking stockholder approval for a reverse stock split of its common stock, with a proposed ratio ranging from one-for-two to one-for-30. The exact ratio will be determined by the board of directors, which also retains the discretion to abandon the split entirely. This proposal is being presented at a virtual Special Meeting on January 15, 2026, where 10,121,060 shares of common stock are outstanding and entitled to vote as of the December 19, 2025 record date. The primary objective of the reverse stock split is likely to increase the per-share trading price to meet Nasdaq's listing requirements, as indicated by the 'Listing Condition' clause. The board of directors unanimously recommends a 'FOR' vote on this Amendment Proposal, which is considered a 'routine' matter, allowing brokers to vote uninstructed shares. The company has not disclosed specific revenue or net income figures in this DEF 14A filing, focusing solely on the procedural aspects of the proposed reverse stock split and meeting logistics. Risks include potential negative market perception and continued share price volatility post-split, despite the aim to maintain Nasdaq listing.

Why It Matters

This reverse stock split is critical for GRI Bio, Inc. as it aims to maintain its listing on The Nasdaq Stock Market LLC, a key factor for institutional investor confidence and liquidity. For investors, a successful split could prevent delisting, but it doesn't fundamentally change the company's valuation or operational health, potentially leading to further price erosion if underlying business issues persist. Employees might see this as a necessary step to stabilize the company's market presence, while customers are unlikely to be directly impacted. Competitively, maintaining a Nasdaq listing helps GRI Bio stay on par with other publicly traded biotech firms, avoiding the stigma and reduced visibility often associated with over-the-counter markets.

Risk Assessment

Risk Level: medium — The risk level is medium because while a reverse stock split can help GRI Bio meet Nasdaq's minimum bid price requirement, it does not address the underlying reasons for the low stock price. The filing explicitly mentions the 'Listing Condition' related to Nasdaq requirements, indicating the company is likely facing delisting. Historically, reverse stock splits often lead to further share price declines post-split, as investor sentiment may view it as a sign of distress rather than strength.

Analyst Insight

Investors should carefully evaluate GRI Bio's fundamentals and long-term prospects beyond this procedural move. While a 'FOR' vote is recommended by the board to maintain Nasdaq listing, consider if the company's core business strategy and financial health justify continued investment, as a reverse split alone rarely signals a turnaround.

Financial Highlights

debt To Equity

N/A

revenue

N/A

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

N/A

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

N/A

Key Numbers

• 10,121,060 — Shares of common stock outstanding (Entitled to vote at the Special Meeting as of December 19, 2025)
• 1-for-2 to 1-for-30 — Reverse stock split ratio range (Proposed range for the Amendment Proposal)
• January 15, 2026 — Special Meeting Date (Date stockholders will vote on the reverse stock split)
• December 19, 2025 — Record Date (Date to determine eligible voters for the Special Meeting)
• $8,500 — Proxy solicitation fee (Paid to Campaign Management, LLC for services)

Key Players & Entities

• GRI Bio, Inc. (company) — Registrant seeking proxy approval
• W. Marc Hertz, Ph.D. (person) — President and Chief Executive Officer of GRI Bio, Inc.
• Leanne Kelly (person) — Corporate Secretary of GRI Bio, Inc.
• The Nasdaq Stock Market LLC (regulator) — Stock exchange with listing requirements
• Campaign Management, LLC (company) — Proxy solicitor retained by GRI Bio, Inc.
• $8,500 (dollar_amount) — Fee for proxy solicitation services
• 10,121,060 (dollar_amount) — Shares of common stock outstanding as of Record Date
• December 19, 2025 (date) — Record Date for Special Meeting
• January 15, 2026 (date) — Date of Special Meeting
• 2223 Avenida de la Playa, Suite 208, La Jolla, CA 92037 (company) — Principal executive offices of GRI Bio, Inc.

FAQ

Risk Factors

• Failure to Meet Nasdaq Listing Requirements [high — market]: The primary purpose of the reverse stock split is to increase the per-share trading price to meet Nasdaq's minimum bid price requirement. Failure to achieve this could result in delisting from the Nasdaq Capital Market, significantly impacting liquidity and investor confidence.
• Negative Market Perception of Reverse Stock Split [medium — market]: Reverse stock splits are often perceived negatively by the market, as they can signal underlying financial distress or an inability to organically grow the stock price. This perception could lead to a decline in stock value even after the split.
• Board Discretion to Abandon Split [low — operational]: The board of directors has the sole discretion to determine the exact ratio of the reverse stock split or to abandon the proposal entirely. This flexibility, while strategic, introduces uncertainty for investors regarding the final outcome.

Industry Context

GRI Bio, Inc. operates in the biotechnology sector, a highly competitive and capital-intensive industry. Companies in this space often face significant challenges in drug development, regulatory approval, and securing funding. The need for a reverse stock split to maintain Nasdaq listing suggests potential pressures related to market valuation and investor confidence, common themes for smaller or development-stage biotech firms.

Regulatory Implications

The primary regulatory implication is the need to comply with Nasdaq's listing rules, specifically the minimum bid price requirement. Failure to meet these requirements could lead to delisting. The reverse stock split itself is a procedural action requiring shareholder approval and adherence to corporate governance standards.

What Investors Should Do

1. Review the proxy statement carefully before the Special Meeting on January 15, 2026.
2. Vote on the Amendment Proposal regarding the reverse stock split.
3. Consider the implications of a reverse stock split on your investment.

Key Dates

• 2026-01-15: Special Meeting of Stockholders — Stockholders will vote on the proposed reverse stock split and adjournment proposal.
• 2025-12-19: Record Date — Determines which stockholders are eligible to vote at the Special Meeting.
• 2025-12-29: Commencement of Mailing of Proxy Materials — Investors begin receiving the official proxy statement and voting instructions.

Glossary

Reverse Stock Split

A corporate action where a company reduces the total number of its outstanding shares by consolidating them into fewer, proportionally more valuable shares. (The primary proposal at the Special Meeting, aimed at increasing the stock's per-share price to meet Nasdaq listing requirements.)

DEF 14A

A proxy statement filing required by the U.S. Securities and Exchange Commission (SEC) for annual or special meetings of shareholders. (This document provides detailed information about the matters to be voted on, including the proposed reverse stock split.)

Record Date

A specific date set by a company to determine which shareholders are eligible to receive dividends, vote on corporate matters, or have other rights. (Establishes the pool of shareholders entitled to vote at the January 15, 2026 Special Meeting.)

Amendment Proposal

A proposal to amend the company's Amended and Restated Certificate of Incorporation to effect the reverse stock split. (This is the core proposal requiring stockholder approval for the reverse stock split to proceed.)

Adjournment Proposal

A proposal to allow the meeting to be postponed or adjourned if there are insufficient votes to approve the primary proposals. (Provides a mechanism to allow for further solicitation of votes if the reverse stock split proposal does not initially pass.)

Year-Over-Year Comparison

This DEF 14A filing focuses exclusively on the procedural aspects of a special meeting and a proposed reverse stock split. It does not provide comparative financial data such as revenue or net income from a previous filing, making a direct year-over-year comparison of key financial metrics impossible based on this document alone. The primary new risk factor highlighted is the immediate need to address Nasdaq listing requirements through the reverse stock split.

Key Financial Figures

• $8,500 — e and information support, for a fee of $8,500, plus reasonable expenses. What does i
• $1.00 — shares of our common stock of at least $1.00 per share (also referred to as the "min
• $35,000,000 — value of listed securities of less than $35,000,000 and annual net income of less than $500
• $500,000 m — ,000 and annual net income of less than $500,000 maintain stockholders' equity of at least
• $2,500,000 — intain stockholders' equity of at least $2,500,000 (the Stockholders' Equity Requirement")

Filing Documents

• gridefinitiveproxystatemen.htm (DEF 14A) — 169KB
• image_0.jpg (GRAPHIC) — 24KB
• screenshot2025-12x18at5184.jpg (GRAPHIC) — 97KB
• screenshot2025-12x18at9174.jpg (GRAPHIC) — 76KB
• 0001824293-25-000173.txt ( ) — 441KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 15

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 15 ADDITIONAL INFORMATION 16 APPENDIX A Appendix A- 1 APPENDIX B Appendix B- 1 i 2223 Avenida de la Playa, Suite 208 La Jolla, CA 92037 PROXY STATEMENT FOR THE SPECIAL MEETING OF STOCKHOLDERS TO BE HELD ON JANUARY 15, 2026 This proxy statement (the "Proxy Statement") is furnished to stockholders of GRI Bio, Inc., a Delaware corporation (the "Company," "we," "us," or "our"), in connection with the solicitation of proxies by our board of directors for use at a special meeting of stockholders to be held on January 15, 2026, and at any adjournment or postponement thereof (our "Special Meeting"). Our Special Meeting will be held at 900 a.m. Eastern time via a live audio webcast at www.virtualshareholdermeeting.comGRI2026SM. On or about December 29, 2025, we will commence mailing of the proxy materials which are also available at www.proxyvote.com. The proxy materials are being sent to stockholders who owned our common stock at the close of business on December 19, 2025, the record date for the Special Meeting (the "Record Date"). This Proxy Statement contains important information for you to consider when deciding how to vote on the matters brought before the meeting. Please read it carefully. Why am I receiving these materials We sent you this Proxy Statement because our board of directors is soliciting your proxy to vote at our Special Meeting. This Proxy Statement summarizes the information you need to vote at our Special Meeting. You do not need to attend our Special Meeting to vote your shares. What proposals will be voted on at the Special Meeting Stockholders will vote on two proposals at the Special Meeting 1. The approval of an amendment to our Amended and Restated Certificate of Incorporation, as amended (the "Amended and Restated Certificate of Incorporation"), to effect a reverse stock split of our common stock by a ratio of not less than one-for-two and not more than one-for-

View Full Filing

View this DEF 14A filing on SEC EDGAR